View Older Stories View More Recent Stories

Apr 17, 2026 08:00AM Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors

Apr 15, 2026 05:31PM Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Apr 15, 2026 07:30AM Terremoto Biosciences Closes $108 Million Series C Financing to Advance Selective AKT1-Inhibitors in Oncology and Hereditary Hemorrhagic Telangiectasia

Apr 14, 2026 02:08PM Galera and Obsidian merge in $350 million all-stock deal

Apr 14, 2026 02:08PM Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement

Apr 14, 2026 08:54AM Obsidian Therapeutics and Galera Therapeutics announce merger with $350M funding

Apr 14, 2026 08:54AM Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement

Apr 14, 2026 06:05AM Jeito Capital leads oversubscribed $75 million Series C in Adcendo ApS to Advance its First- and Best-in-class Clinical ADC¹ Pipeline in Oncology

Apr 14, 2026 06:00AM Adcendo ApS Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline

Apr 13, 2026 05:23PM Form SCHEDULE 13G/A Adicet Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Apr 10, 2026 06:25PM Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Apr 8, 2026 06:45PM Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Apr 8, 2026 07:00AM Incyclix Bio Raises Additional $5 Million in Series B Financing to Advance Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors

Apr 7, 2026 06:00PM Form SCHEDULE 13G Aclaris Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Apr 7, 2026 04:14PM Form SCHEDULE 13G OnKure Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Apr 6, 2026 06:55PM Form SCHEDULE 13G Zai Lab Ltd Filed by: RA CAPITAL MANAGEMENT, L.P.

Apr 6, 2026 07:00AM Stipple Bio Emerges From Stealth with Oversubscribed $100 Million Series A Financing to Advance STP-100 into Early Clinical Studies and Advance a Precision Oncology Pipeline that Leverages its Pointil

Apr 2, 2026 04:47PM Form SCHEDULE 13G Karyopharm Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.

Apr 1, 2026 05:10PM Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Apr 1, 2026 07:05AM Cyclerion and Korsana announce $380 million merger deal

Apr 1, 2026 07:05AM Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Mar 31, 2026 07:30AM CellCentric Initiates DOMMINO-1, a Pivotal Phase 2 Clinical Trial of Inobrodib in Combination with Pomalidomide and Dexamethasone (InoPd) in Relapsed or Refractory Multiple Myeloma

Mar 30, 2026 08:38PM Form SCHEDULE 13G Xencor Inc Filed by: RA CAPITAL MANAGEMENT, L.P.

Mar 30, 2026 08:32PM Form SCHEDULE 13D/A Wave Life Sciences Ltd. Filed by: RA CAPITAL MANAGEMENT, L.P.

Mar 30, 2026 08:01AM Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 27, 2026 09:00AM Navigator Medicines Advances NAV-240 into Phase 2a and NAV-242 into the Clinic, Supported by New Positive Data Presented at American Academy of Dermatology (AAD) Annual Meeting 2026

Mar 27, 2026 08:02AM OnKure raises $150 million to advance cancer treatment programs

Mar 27, 2026 08:00AM OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies

Mar 26, 2026 04:05PM SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update

Mar 26, 2026 04:05PM Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

Mar 26, 2026 07:30AM Pinnacle Medicines, a Pioneer of Oral Peptide Therapeutics, Announces Oversubscribed $89 Million Series B Financing to Advance Pipeline into Clinical Trials

Mar 25, 2026 04:05PM Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights

Mar 24, 2026 07:02AM Karyopharm raises $30 million in private placement with RA Capital

Mar 24, 2026 07:01AM Karyopharm Announces $30 Million Private Placement with RA Capital

Mar 23, 2026 04:28PM Form SCHEDULE 13D/A Acrivon Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Mar 23, 2026 04:26PM Form SCHEDULE 13D/A SAB Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Mar 20, 2026 04:13PM Form SCHEDULE 13G Equillium, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Mar 18, 2026 06:00AM Ovid Therapeutics prices $60 million private placement for drug development

Mar 18, 2026 06:00AM Ovid Therapeutics Announces Pricing of $60 Million Private Placement

Mar 17, 2026 06:50PM Form SCHEDULE 13D/A Solid Biosciences Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Mar 17, 2026 04:36PM Form SCHEDULE 13D/A Acumen Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.

Mar 16, 2026 04:15PM Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Mar 16, 2026 06:30AM Acumen Pharmaceuticals raises $35.75 million in private placement

Mar 16, 2026 06:30AM Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

Mar 13, 2026 04:45PM Network 1 Reports 2025 Year End Financial Results

Mar 13, 2026 08:01AM Equillium raises $35 million from RA Capital Management

Mar 13, 2026 08:00AM Equillium Announces $35 Million Financing with RA Capital Management

Mar 12, 2026 08:00AM Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates

Mar 11, 2026 04:43PM Form SCHEDULE 13D/A SAB Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Mar 10, 2026 04:39PM Form SCHEDULE 13D/A Solid Biosciences Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

View More Recent Stories View Older Stories